Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
: V2 C8 V' ~% v5 o" b# E: dNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 / Y U' Q' u1 i) n) Y3 b. |& ^. q* j
+ Author Affiliations
8 z R' U+ @; X! U% i- c5 {
d7 T. {* \. L* C7 T7 l% U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 I4 _7 P8 C0 ]$ N9 S k2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan / n& u. V9 h0 y9 G5 Z5 ]
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
$ N0 D0 b! r: ?) n: n7 \4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
/ _# H5 n5 Q4 H) m3 j5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
2 a6 k5 p/ [2 f8 I; K' T; ^5 M6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
4 X8 Q3 @2 j# }9 e# I. f7Kinki University School of Medicine, Osaka 589-8511, Japan % O* d m, `$ ]0 U' E, D
8Izumi Municipal Hospital, Osaka 594-0071, Japan
3 o0 c) r( K# A9 Y+ i- k+ g9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( j4 H4 v$ E" a" RCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp $ z0 ]8 L8 z# Y- T0 U
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 z+ l* D1 }: |& M, A: Q G& K- t* g4 K' `/ {, ~. l. I" }1 w+ M
|